FDA crackdown on Cipla Pharma's Pune unit, license cancelled over 'unauthorised promotional text'
The FDA seized Reactin Plus stock worth ₹11.19 lakh and ordered the firm to recall the drug from the market.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.hindustantimes.com — the content belongs to Hindustan Times - India News.